Published in J Am Acad Dermatol on December 01, 2002
Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol (2012) 2.14
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol (2005) 2.01
A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol (2008) 1.86
Ocular pemphigus. J Am Acad Dermatol (2005) 1.56
Diagnostic features of pemphigus vulgaris in patients with bullous pemphigoid. Molecular analysis of autoantibody profile. Dermatology (2002) 1.38
Role of collagen-binding heat shock protein 47 and transforming growth factor-beta1 in conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2003) 1.14
Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol (2009) 1.09
Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol (2006) 0.98
Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother (2007) 0.95
Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol (2006) 0.94
Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology (2010) 0.93
Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol (2006) 0.92
Role of connective tissue growth factor in the pathogenesis of conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2003) 0.91
Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol (2013) 0.91
The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology (2002) 0.89
Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol (2011) 0.87
Role of enhanced expression of m-CSF in conjunctiva affected by cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2002) 0.86
Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol (2004) 0.82
Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol (2002) 0.82
Relationship between radiation therapy and bullous pemphigoid. Dermatology (2014) 0.82
Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother (2007) 0.81
Concurrence of systemic lupus erythematosus and pemphigus: coincidence or correlation? Dermatology (2007) 0.81
Effects of IL-4 on conjunctival fibroblasts: possible role in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2003) 0.81
Identification of an epitope within human integrin alpha 6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid. J Immunol (2006) 0.81
Serological studies in bullous pemphigoid: a literature review of antibody titers at presentation and in clinical remission. Acta Derm Venereol (2010) 0.80
A current review of juvenile pemphigus vulgaris: analysis of data on clinical outcomes. Am J Clin Dermatol (2010) 0.80
King Tutankhamun's family and demise. JAMA (2010) 0.79
Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from pemphigus vulgaris patient. Autoimmunity (2002) 0.79
Anal involvement in pemphigus vulgaris. Dis Colon Rectum (2006) 0.79
Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology (2004) 0.78
The molecular basis for the presence of two autoimmune diseases occurring simultaneously--preliminary observations based on computer analysis. Autoimmunity (2011) 0.78
Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb) (2012) 0.78
A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol (2004) 0.78
Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol (2010) 0.78
Role of macrophage migration inhibitory factor in conjunctival pathology in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci (2004) 0.78
Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol (2002) 0.77
Blistering diseases in the elderly: diagnosis and treatment. Dermatol Clin (2004) 0.77
Involvement of the female genital tract in pemphigus vulgaris. Obstet Gynecol (2005) 0.77
Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol (2002) 0.77
Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm (2006) 0.77
Biology of interleukin-5 in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol (2002) 0.76
Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study. Ann Pharmacother (2005) 0.76
Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev (2010) 0.76
Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin Pharmacother (2011) 0.76
Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol (2009) 0.76
Expression profiles of collagens, HSP47, TGF-beta1, MMPs and TIMPs in epidermolysis bullosa acquisita. Cytokine (2003) 0.75
Dual diagnosis of pemphigus vulgaris and connective tissue disease. J Am Acad Dermatol (2006) 0.75
Association between cancer and immunosuppressive therapy--analysis of selected studies in pemphigus and pemphigoid. Ann Pharmacother (2010) 0.75
Reply to "Treatment of mucous membrane pemphigoid with rituximab". J Am Acad Dermatol (2013) 0.75
Do the telangiectases of hereditary hemorrhagic telangiectasia and the calcinosis, Raynaud's disease, sclerodactyly, telangiectasia variant of scleroderma have a common etiology? Dermatology (2006) 0.75
Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin. J Oral Pathol Med (2007) 0.75
Recent advances in the treatment of autoimmune mucocutaneous blistering diseases. Int J Periodontics Restorative Dent (2007) 0.75
Chronic cicatrizing conjunctivitis in a patient with epidermolysis bullosa acquisita. Arch Ophthalmol (2006) 0.75
Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris. Pediatr Dermatol (2011) 0.75
Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab. Ann Pharmacother (2013) 0.75
Identification of epitopes within integrin β4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report. Invest Ophthalmol Vis Sci (2013) 0.75
Possible in vitro model of toxic epidermal necrolysis. Arch Ophthalmol (2011) 0.75